BARD1 Life Sciences Limited announce the appointment of Dr. Gregory Rice PhD as Chief Scientific Officer (CSO), effective 20 September 2021. Dr. Rice will lead the Company's Research and Development (R&D) programs with responsibility for providing scientific leadership, planning R&D strategies, implementing best practice and advancing its diagnostic development programs to achieve value-generating clinical and commercial milestones. Dr. Greg Rice PhD, commercial scientist with over 30 years' expertise and experience in oncology, perinatology, exosome- based research, clinical translational research, IVD development and commercialisation. He has held senior academic appointments, co-founded hospital-based clinical research centres in both oncology and perinatology, and co-founded and led diagnostic companies. He is scientist with a strong international profile and clinical research networks. He has published more than 280 peer-reviewed scientific publications and is a regular invited speaker at international conferences.